Adlai Nortye gets Reolysin rights from Oncolytics Biotech

15:40 EDT 13 Mar 2018 | Elsevier Business Intelligence

Oncolytics Biotech Inc. granted Adlai Nortye exclusive rights to develop and sell its cancer therapy Reolysin (pelareorep) in...

Original Article: Adlai Nortye gets Reolysin rights from Oncolytics Biotech

NEXT ARTICLE

More From BioPortfolio on "Adlai Nortye gets Reolysin rights from Oncolytics Biotech"